The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
BROMPHENIRAMINE MALEATE and PSEUDOEPHEDRINE HYDROCHLORIDE · BROMPHENIRAMINE MALEATE 1 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 15 mg/5mL · Liquid · Oral · Edwards Pharmaceuticals, Inc.
NDC 00485-0206-16 · 473 mL in 1 BOTTLE, PLASTIC · UNAPPROVED DRUG OTHER · View full market →
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Edwards Pharmaceuticals, Inc. | BROMPHENIRAMINE MALEATE 1 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 15 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Rynex Pse — NDC 00485-0206-16," retrieved September 3, 2026, https://drugdashboards.com/drug/00485020616.
Free to cite with attribution — see how the data is put together.